Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis - Bright Minds Biosciences ( NASDAQ:DRUG ) , Firefly Neuroscience ( NASDAQ:AIFF )

21 hours ago

Firefly Neuroscience, Inc. AIFF announced a collaboration with Bright Minds Biosciences Inc. DRUG to analyze data from the first-in-human Phase 1 study of BMB-101, Bright Minds' lead compound for neuropsychiatric disorders and refractory epilepsy.

Ticker	Sentiment	Impact
DRUG	Somewhat Bullish	29 %